LOG IN
SIGN UP
MARKET
ONTX
ONTX
Onconova Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.320
+0.025
+1.93%
Opening 10:38 07/05 EDT
OPEN
1.270
PREV CLOSE
1.295
HIGH
1.330
LOW
1.270
VOLUME
19.41K
TURNOVER
17.22K
52 WEEK HIGH
6.77
52 WEEK LOW
1.000
MARKET CAP
27.58M
P/E (TTM)
-1.5327
1D
5D
1M
3M
1Y
5Y
Onconova Therapeutics appoints company's CFO Mark Guerin as the new COO
Onconova Therapeutics (NASDAQ:ONTX) appoints Mark Guerin as the COO in addition to his current role as company’s CFO. Mr. Guerin has worked in numerous roles at the company since he joined in September
Seekingalpha · 06/13 13:52
Sector Update: Health Care Stocks Fall in Early Monday Afternoon Trading
MT Newswires · 06/13 13:01
Onconova Therapeutics Gives CFO Mark Guerin Additional Role of Chief Operating Officer
MT Newswires · 06/13 10:42
53 Stocks Moving In Thursday's Mid-Day Session
Gainers
Benzinga · 06/02 16:18
BRIEF-Onconova Therapeutics Announces Abstract At The Asco Annual Meeting Highlighting Narazaciclib’S Differentiated Inhibitory And Improved Safety Profile In Preclinical Models
reuters.com · 05/26 23:54
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitorsNEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinic...
GlobeNewswire · 05/26 21:10
Is Onconova Therapeutics (NASDAQ:ONTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 05/15 12:04
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Zacks · 05/12 14:20
No Data
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 4 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONTX stock price target is 10.00 with a high estimate of 12.00 and a low estimate of 7.00.
Current 1.345
EPS
Actual
Estimate
-0.26-0.20-0.13-0.07
Institutional Holdings
Institutions: 48
Institutional Holdings: 3.33M
% Owned: 15.95%
Shares Outstanding: 20.90M
TypeInstitutionsShares
Increased
9
289.33K
New
2
11.48K
Decreased
6
377.64K
Sold Out
8
370.25K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
-0.81%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Non-Executive Chairman/Independent Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer/Chief Operating Officer
Mark Guerin
Other
Mark Gelder
Other
Adar Silverstein
Independent Director
Jerome Groopman
Independent Director
Viren Mehta
Independent Director
M. Teresa Shoemaker
Independent Director
Jack Stover
No Data
No Data
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib is a multi-targeted kinase inhibitor targeting cyclin-dependent kinases (CDK) 2, 4, 6, and 9, AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R). It is supporting investigator-initiated studies (ISS) that are exploring the use of rigosertib for cancers driven by mutated Ras genes, including a Phase 1/2a study of rigosertib in combination with a PD-1 inhibitor.
Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.